Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 14/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 14/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 14/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 14/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 14/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 14/20 | 0.52 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 2/20 | 0.46 |
| ▸ | GSAP | A4D1B5 | 1/20 | 0.42 |
| ▸ | CCKBR | P32239 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412059 | 0.85 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4419147 | 0.78 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4417467 | 0.76 | PSEN1 (0.68) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4417158 | 0.75 | CCKBR (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6301505 | 0.74 | XIAP (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4422325 | 0.73 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL6301491 | 0.71 | CCKBR (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9793668 | 0.70 | CCKBR (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4992726 | 0.70 | CCKBR (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7847907 | 0.70 | CCKBR (0.54) | XIAPCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838455-B2 | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2005-01-04 | — | — | US | claimed |
| US-20030149022-A1 | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | AUDIA JAMES E (US) | 2003-08-07 | — | — | US | claimed |
| US-6552013-B1 | For therapy of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-04-22 | — | — | US | claimed |
| EP-1089977-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 2001-04-11 | — | — | EP | claimed |
| WO-1999067219-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | claimed |
| US-6838455-B2 | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2005-01-04 | — | — | US | disclosed |
| US-20030149022-A1 | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | AUDIA JAMES E (US) | 2003-08-07 | — | — | US | disclosed |
| US-6552013-B1 | For therapy of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149022-A1 | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | APP, IAPP, BACE1 | PSEN1 5/4885PSEN2 6/4885APH1B 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.